Lomustine
Active ingredient: Lomustine
In short: Lomustine Capsules are indicated for the treatment of patients with primary and metastatic brain tumors following appropriate surgical and/or radiotherapeutic procedures. Lomustine Capsules are indicated as a component of combination chemotherapy for the treatment of patients with Hodgkin’s lymphoma
What is Lomustine used for?
Lomustine Capsules are indicated for the treatment of patients with primary and metastatic brain tumors following appropriate surgical and/or radiotherapeutic procedures.
Lomustine Capsules are indicated as a component of combination chemotherapy for the treatment of patients with Hodgkin’s lymphoma whose disease has progressed following initial chemotherapy.
âš Boxed warning (FDA's strongest warning)
DELAYED MYELOSUPPRESSION
Lomustine Capsules cause myelosuppression including fatal myelosuppression. Myelosuppression is delayed, dose-related, and cumulative; occurring 4 to 6 weeks after drug administration and persisting for 1 to 2 weeks. Thrombocytopenia is generally more severe than leukopenia. Cumulative myelosuppression from Lomustine Capsules is manifested by greater severity and longer duration of cytopenias. Monitor blood counts for at least 6 weeks after each dose. Do not give Lomustine Capsules more frequently than every 6 weeks .
RISK OF OVERDOSAGE
PRESCRIBE, DISPENSE, AND ADMINISTER ONLY ENOUGH CAPSULES FOR ONE DOSE. Fatal toxicity occurs with overdosage of Lomustine Capsules. Both physician and pharmacist should emphasize to the patient that only one dose of Lomustine Capsules is taken every 6 weeks [see
Dosage and Administration (2.1), Warnings and Precautions (5.2), Overdosage (10)
].
Lomustine dosage
PRESCRIBE ONLY ONE DOSE FOR EACH TREATMENT CYCLE. DO NOT DISPENSE ENTIRE CONTAINER. Dispense only a sufficient number of capsules for one dose.
Confirm the total dose prescribed by the physician and the appropriate combination of capsule strengths.
Dispense only the appropriate number of Lomustine Capsules required for the administration of a single dose.
The prescribed dose may consist of two or more different strengths and colors of capsules.
Instruct patients that Lomustine Capsules are taken as a single oral dose and will not be repeated for at least 6 weeks. Taking more than the recommended dose causes toxicities, including fatal outcomes .
Lomustine Capsules is a cytotoxic drug. Follow applicable special handling and disposal procedures.1
To minimize the risk of dermal exposure, always wear impervious gloves when handling bottles containing Lomustine Capsules. Do not break Lomustine Capsules; avoid exposure to broken capsules. If dermal contact occurs, wash areas of skin contact immediately and thoroughly.
The recommended dose of Lomustine Capsules in adult and pediatric patients is 130 mg/m2 taken as a single oral dose every 6 weeks. Round doses to the nearest 5 mg. Give as a single oral dose and do not repeat for at least 6 weeks. Reduce dose to 100 mg/m2 every 6 weeks in patients with compromised bone marrow function. Also reduce dose accordingly when using with other myelosuppressive drugs.
Perform weekly complete blood counts and withhold each subsequent dose for more than 6 weeks if needed until platelet counts recover to 100,000/mm3 or greater and leukocytes recover to 4000/mm3 or greater .
Modify each dose of Lomustine Capsules according to the hematologic response of the preceding dose as described in Table 1:
Table 1. Dose Modifications for Lomustine Capsules
Nadir After Prior Dose | Dose Adjustment
Leukocytes (/mm3) | Platelets (/mm3)
≥ 4000 | ≥ 100,000 | None
3000 – 3999 | 75,000 – 99,999 | None
2000 – 2999 | 25,000 – 74,999 | Reduce dose by 30%
< 2000 | < 25,000 | Reduce dose by 50%
How to take Lomustine — instructions & advice from the label
Myelosuppression
Advise patients that periodic assessment of their blood counts are required. Advise patients to contact their healthcare provider for new onset of bleeding or fever or symptoms of infection .
Overdosage
Advise patients that toxicity including fatal toxicity occurs with Lomustine Capsules overdosage .
Advise patients to take Lomustine Capsules as directed:
Lomustine Capsules are taken as a single oral dose that will not be repeated for at least 6 weeks.
Use of the recommended dose at less than 6 week intervals leads to toxicities including fatal toxicities.
Each dose may consist of 2 or more different strengths and colors of capsules.
Pulmonary Fibrosis
Advise patients to contact their healthcare provider for new or worsening cough, chest pain, or shortness of breath .
Hepatotoxicity
Inform patients that Lomustine Capsules can cause hepatotoxicity and that liver function monitoring during treatment is necessary .
Nephrotoxicity
Inform patients that Lomustine Capsules can cause nephrotoxicity and that renal function and electrolyte monitoring during treatment is necessary . …
Warnings & precautions
Do not take this medicine if: None.
Lomustine Capsules cause myelosuppression that can result in fatal infections and bleeding. Myelosuppression from Lomustine Capsules is delayed, dose-related, and cumulative. It usually occurs 4 to 6 weeks after drug administration and persists for 1 to 2 weeks. Thrombocytopenia is generally more severe than leukopenia. Cumulative myelosuppression from Lomustine Capsules is manifested by greater severity and longer duration of cytopenias.
Monitor blood counts for at least 6 weeks after each dose. Do not give Lomustine Capsules more frequently than every 6 weeks. Adjust dose based on nadir blood counts from prior dose .
Fatal toxicity occurs with overdosage of Lomustine Capsules. Dispensing or administering more than one dose can lead to fatal toxicity.
Prescribe only one dose at a time. Dispense only enough capsules for one dose. Both physician and pharmacist should emphasize to the patient that only one dose of Lomustine Capsules is taken every 6 weeks .
Pulmonary toxicity characterized by pulmonary infiltrates and/or fibrosis occurs with Lomustine Capsules. Patients with a baseline below 70% of the predicted Forced Vital Capacity (FVC) or Carbon Monoxide Diffusing Capacity (DLCO) are at increased risk. The onset of pulmonary toxicity occurs after an interval of 6 months or longer from the start of therapy, with cumulative doses of Lomustine Capsules usually greater than 1100 mg/m2.
Obtain baseline pulmonary function tests prior to initiating treatment and repeat frequently during treatment. Permanently discontinue Lomustine Capsules in patients diagnosed with pulmonary fibrosis.
Secondary malignancies, including acute leukemia and myelodysplasia, occur with long term use.
Hepatic toxicity, manifested by increased levels of transaminases, alkaline phosphatase, and bilirubin occurs with Lomustine Capsules.
Monitor liver function. …
Lomustine side effects
The following serious adverse reactions are discussed in greater detail in other sections of the labeling:
Delayed myelosuppression
Risks of overdosage
Pulmonary toxicity
Secondary malignancies
Hepatotoxicity
Nephrotoxicity
The following adverse reactions associated with the use of Lomustine Capsules were identified in clinical trials or postmarketing reports. Because these reactions were reported from a population of uncertain size, it is not possible to estimate their frequency, reliability, or establish a causal relationship to drug exposure.
Gastrointestinal disorders: nausea, vomiting, and stomatitis
Ocular disorders: optic atrophy, visual disturbances, and blindness
Neurologic disorders: disorientation, lethargy, ataxia, and dysarthria
Other: alopecia
About this medicine
Lomustine Capsules, USP (lomustine) is an alkylating drug for oral administration. The chemical name for lomustine is 1-(2-chloro-ethyl)-3-cyclohexyl-1-nitrosourea and the molecular formula is C9H16ClN3O2. The molecular weight is 233.71. Lomustine is a yellow powder, which is soluble in 10% ethanol (0.05 mg per mL) and in absolute alcohol (70 mg per mL). Lomustine is insoluble in water (<0.05 mg per mL).
The chemical structure is:
Lomustine Capsules, USP are supplied as 10 mg, 40 mg, and 100 mg capsules and contain the following inactive ingredients: magnesium stearate NF and mannitol USP. The 10 mg capsule shells are composed of gelatin and titanium dioxide. The 40 mg and 100 mg capsule shells are composed of FD&C blue #1, gelatin, iron oxide black, iron oxide yellow, and titanium dioxide. The capsules are printed with black ink composed of iron oxide black, potassium hydroxide, propylene glycol, shellac, and strong ammonia solution.
FDA approved dissolution method is not listed in the USP Monograph for Lomustine Capsules, USP, 10 mg, 40 mg, and 100 mg. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 916dfac8-da11-40e4-9e44-a909e29a6b5f. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate